Invigor Medical vs Teladoc Weight Management
A detailed head-to-head comparison of Invigor Medical and Teladoc Weight Management — pricing, peptides, consultation models, and patient reviews.
At a Glance
RatingNo reviews
Starting PriceN/A
Peptides3
ConsultationHybrid
Lab TestingNo
Shipping3-5 business days
Pros
- Broad treatment menu
- Men's anti-aging focus
- Experienced provider network
- Coordinated multi-protocol management
Cons
- Regulatory uncertainty on GLP-1 compounding
- Peptide protocols are not FDA-approved
- Men only
- Complexity requires patient education
- Async model limits clinical oversight
RatingNo reviews
Starting PriceN/A
Peptides2
ConsultationVideo Telehealth
Lab TestingNo
Shipping3-5 business days
Pros
- Massive scale and established telehealth infrastructure (NYSE: TDOC)
- Often available through employer health plans at subsidized rates
- Insurance integration and prior authorization support
- Video consultations with licensed providers
- Behavioral coaching included in weight management program
Cons
- Weight management is an add-on to a general telehealth platform
- No compounded medication options
- Not the most competitive cash-pay option for uninsured patients
- Prior authorization process can delay treatment start
- Less specialized GLP-1 expertise compared to dedicated weight loss platforms
Pros & Cons
Peptide Pricing Comparison
| Peptide | Invigor Medical | Teladoc Weight Management |
|---|---|---|
| BPC-157 | Price unavailable | Not offered |
| Semaglutide | Price unavailable | Price unavailable |
| Tirzepatide | Price unavailable | Price unavailable |
Frequently Asked Questions
Is Invigor Medical or Teladoc Weight Management better?
Invigor Medical offers 3 peptides and hybrid consultations. Teladoc Weight Management offers 2 peptides and video telehealth consultations. The best choice depends on which peptides you need, your budget, and preferred consultation model.
Which is cheaper, Invigor Medical or Teladoc Weight Management?
See the pricing table above for a detailed comparison.